Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
Phase 1
Completed
- Conditions
- Opioid-Related DisordersSubstance-Related Disorders
- Registration Number
- NCT00000358
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which lofexidine modulates opioid withdrawal symptoms in patients with opioid-related disorders?
How does lofexidine compare to clonidine in managing opioid withdrawal signs and symptoms in clinical settings?
Are there specific biomarkers that can predict patient response to lofexidine treatment for opioid withdrawal?
What are the potential adverse events associated with lofexidine use in opioid withdrawal and how are they managed?
What is the role of lofexidine in combination therapies for opioid-related disorders compared to other alpha-2 adrenergic agonists?
Trial Locations
- Locations (1)
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
University of Pennsylvania🇺🇸Philadelphia, Pennsylvania, United States